Theracarb Inc. is a private Canadian biotechnology company developing and commercializing technologies derived from the Alberta Ingenuity Center for Carbohydrate Sciences (AICCS), a research center funded by Alberta Ingenuity, a $1B endowed fund. Theracarb's development programs span vaccine and therapeutic treatment options in two core disease areas: infectious diseases and neurodegenerative diseases.

Theracarb News

August 13, 2009:
Theracarb Inc. Chief Scientific Officer receives highest honor as Distinguished University of Alberta Professor View.

July 27, 2009:
Theracarb Inc. Announces Change in Executive Leadership View.

April 24, 2009:
TheraCarb Inc. Receives Notice of Allowance for US Patent
View.

More...